Merck KGaA’s prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration’s breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer’s Xalkori drug was given the designation https://ift.tt/31em9it last year.

source https://finance.yahoo.com/news/merck-kgaa-lung-cancer-drug-080023527.html?.tsrc=rss